DUEARITY AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.356 SEK | -1.11% |
|
-13.06% | -83.96% |
| 11/03 | Duearity Unit Signs US Distribution Deal With Westone Laboratories | MT |
| 10/03 | Duearity Americas Inc Enters into an Agreement with Westone Laboratories | CI |
| Sales 2022 | - | Sales 2023 | 1.65M 155K 12.88M | Capitalization | 53.92M 5.06M 420M |
|---|---|---|---|---|---|
| Net income 2022 | -19M -1.78M -148M | Net income 2023 | -26M -2.44M -202M | EV / Sales 2022 | - |
| Net cash position 2022 | 5.52M 518K 43.02M | Net Debt 2023 | 10.23M 959K 79.67M | EV / Sales 2023 | 38.8 x |
| P/E ratio 2022 |
-5.33
x | P/E ratio 2023 |
-1.57
x | Employees | 2 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 56.72% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.11% | ||
| 1 week | -13.06% | ||
| Current month | -11.33% | ||
| 1 month | -1.79% | ||
| 3 months | -78.81% | ||
| 6 months | -84.11% | ||
| Current year | -83.96% |
1 week
0.34
0.41
1 month
0.330.43
Current year
0.252.79
1 year
0.259.00
3 years
0.2527.00
5 years
0.2527.00
10 years
0.2527.00
| Managers | Title | Age | Since |
|---|---|---|---|
Arash Golshenas
FOU | Founder | 40 | 08/20/08 |
Alexandra Arndt
FOU | Founder | 51 | 08/20/08 |
Fredrik Westman
CEO | Chief Executive Officer | 52 | 08/20/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eva Helena Vati
BRD | Director/Board Member | 48 | 01/21/01 |
Peter Arndt
FOU | Founder | 57 | 08/20/08 |
Ali Jehanfard
FOU | Founder | 42 | 08/20/08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/24/24 | 0.356 | -1.11% | 149,371 |
| 23/24/23 | 0.36 | -5.01% | 9,596 |
| 22/24/22 | 0.379 | +3.13% | 19,026 |
| 21/24/21 | 0.3675 | -6.96% | 177,987 |
| 20/24/20 | 0.395 | -3.54% | 26,703 |
Delayed Quote Nasdaq Stockholm, May 24, 2024 at 08:50 pm IST
More quotes
Duearity AB is a Sweden-based medical technology company. The Company's product is Tinearity G1. Tinearity G1 is a medical device that helps with tinnitus treatment. Tinearity G1 is based on Tinnitus Retraining Therapy, a white noise treatment that has been used clinically for several decades. Tinearity G1 consists of sound elements that lead white noise to the inner ear via the skull bone. The method is non-invasive and the ear canal is not affected.
Calendar
22/08/2024
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -83.96% | 881K | |
| +5.91% | 32.95B | |
| +20.73% | 8.01B | |
| +34.25% | 4.38B | |
| -29.52% | 2.67B | |
| -13.29% | 1.5B | |
| -28.02% | 1.27B | |
| -30.53% | 1.2B | |
| +11.35% | 996M | |
| -38.17% | 864M |
- Stock Market
- Equities
- DEAR Stock
